Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/32235
Type
ArticleCopyright
Restricted access
Collections
- INI - Artigos de Periódicos [3498]
Metadata
Show full item record
YELLOW FEVER
Affilliation
Hookipa Biotech AG. Vienna, Austria / PaxVax Inc. Menlo Park Redwood City, CA, USA.
Instituto Evandro Chagas. National Reference Laboratory of Arboviruses. Department of Arbovirology and Hemorrhagic Fevers. Ananindeua, Brazil / Instituto Evandro Chagas. National Institute of Science and Technology for Viral Hemorrhagic Fevers. Ananindeua, Brazil / Instituto Evandro Chagas. PAHO/WHO Collaborating Center for Arbovirus Research and Diagnostic Reference. Ananindeua, PA, Brazil / Pará State University. Belém, PA, Brazil.
Instituto Evandro Chagas. National Reference Laboratory of Arboviruses. Department of Arbovirology and Hemorrhagic Fevers. Ananindeua, Brazil / Instituto Evandro Chagas. National Institute of Science and Technology for Viral Hemorrhagic Fevers. Ananindeua, Brazil / Instituto Evandro Chagas. PAHO/WHO Collaborating Center for Arbovirus Research and Diagnostic Reference. Ananindeua, PA, Brazil / Pará State University. Belém, PA, Brazil.
Abstract
Yellow fever, a mosquito-borne flavivirus disease occurs in tropical areas of South America and Africa. It is a disease of major historical importance, but remains a threat to travelers to and residents of endemic areas despite the availability of an effective vaccine for nearly 70 years. An important aspect is the receptivity of many non-endemic areas to introduction and spread of yellow fever. This paper reviews the clinical aspects, pathogenesis, and epidemiology of yellow fever, with an emphasis on recent changes in the distribution and incidence of the disease. Recent knowledge about yellow fever 17D vaccine mechanism of action and safety are discussed.
Share